Effect of pharmacogenomics on beta receptor blockers

Shu-chun LI,Jie YANG,Wen-huan SUN

DOI: https://doi.org/10.3969/j.issn.1000-2162.2014.01.016

2014-01-01

Abstract:Beta receptor blockers are widely used in the treatment of various cardiovascular diseases, but their curative effects have obvious difference and produce adverse reactions. Studies have shown that 20 to 95 percent of individual differences attribute to genetic polymorphism. Thus,this paper comments on the effect of pharmacogenomics on beta receptor blockers in order to guide the clinical use of drugs. Based on the research literature,according to the beta receptor blockers in treatment of hypertension,coronary heart disease,heart failure and other cardiovascular disease,this paper comprehensively analyses the correlation between differences in drug efficacy and genetic differences. CYP2D6* 10,β1-AR389 and G-protein alpha subunit CC allelotype can affect the efficacy of beta receptor blockers; the polymorphism of ADRB2 doesn't affect the efficacy of beta receptor blockers; whether and how other related gene polymorphisms,such as ADRB3,α1D receptor and ACE affect the efficacy of beta receptor blockers need further study.